This site uses cookies.
Some of these cookies are essential to the operation of the site,
while others help to improve your experience by providing insights into how the site is being used.
For more information, please see the ProZ.com privacy policy.
Traduttore e/o interprete freelance, Membro verificato
Data security
This person has a SecurePRO™ card. Because this person is not a ProZ.com Plus subscriber, to view his or her SecurePRO™ card you must be a ProZ.com Business member or Plus subscriber.
Affiliazioni
This person is not affiliated with any business or Blue Board record at ProZ.com.
Servizi
Translation, Interpreting, Editing/proofreading
Esperienza
Specializzazione:
Medicina: Strumentazione
Medicina: Sistema sanitario
Medico: Odontoiatria
Medicina: Cardiologia
Medicina (generale)
Medicina: Farmaceutica
Tariffe
Da Inglese a Spagnolo - Tariffe: 0.06 - 0.07 EUR a parola / 20 - 25 EUR all'ora Da Inglese a Catalano - Tariffe: 0.06 - 0.07 EUR a parola / 20 - 25 EUR all'ora Da Tedesco a Spagnolo - Tariffe: 0.07 - 0.08 EUR a parola / 20 - 25 EUR all'ora Da Tedesco a Catalano - Tariffe: 0.07 - 0.08 EUR a parola / 20 - 25 EUR all'ora Da Francese a Spagnolo - Tariffe: 0.06 - 0.07 EUR a parola / 20 - 25 EUR all'ora
Da Francese a Catalano - Tariffe: 0.06 - 0.07 EUR a parola / 20 - 25 EUR all'ora Da Italiano a Spagnolo - Tariffe: 0.06 - 0.07 EUR a parola / 20 - 25 EUR all'ora Da Italiano a Catalano - Tariffe: 0.06 - 0.07 EUR a parola / 20 - 25 EUR all'ora Da Catalano a Spagnolo - Tariffe: 0.04 - 0.05 EUR a parola / 20 - 25 EUR all'ora Da Spagnolo a Catalano - Tariffe: 0.04 - 0.05 EUR a parola / 20 - 25 EUR all'ora
More
Less
Payment methods accepted
Bonifico bancario, PayPal
Portfolio
Traduzioni di prova presentate: 1
Da Inglese a Spagnolo: SAR650984: A NEW “BLOCKBUSTER” DRUG FOR MYELOMA General field: Medico/Sanitario Detailed field: Medicina: Sistema sanitario
Testo originale - Inglese Myeloma Today in conversation with Dr. Thomas Martin
Dr. Thomas Martin, a member of the International Myeloma Working Group (IMWG), is associate director of the myeloma program at University of California San Francisco (UCSF) Medical Center. More patients have been treated with Sanofi’s new anti-CD38 mono¬clonal antibody, SAR650984, in Dr. Martin’s clinical trials at UCSF than at any other institution in the world.
Please give us some context for the use of SAR650984 in myeloma.
In the last 5 to 10 years, treatment of multiple myeloma has revolved around two types of drugs, proteasome inhibitors Velcade® (bortezomib) and Kyprolis® (carfilzomib) and immunomodulatory drugs (a.k.a. IMiDs®) such as Thalomid® (thalidomide), Revlimid® (lenalidomide), and Pomalyst® (pomalidomide). I call these drugs “blockbusters” because we know they have significant single-agent activity in myeloma, meaning that they produce good responses when used alone, without the addition of other anti-myeloma therapies. In my opinion, the monoclonal antibod¬ies including SAR650984 (an anti-CD38 monoclonal antibody) also have the potential to be “blockbuster” drugs because, in early phase trials, we have seen significant responses (specifically with anti-CD38 antibodies like SAR650984) in heavily pretreated myeloma patients whose myeloma has failed to respond to other therapies.
Monoclonal antibodies are a new class of immunotherapy drugs that have been widely tested and selectively approved in other cancers. Elotuzumab, an anti-CS1 monoclonal antibody, was the first MAb successfully tested in myeloma, and it is now in phase III trials in combination with Revlimid plus dexamethasone for both newly diagnosed and relapsed/refractory myeloma. While it has been very effective in combination with Revlimid/dexamethasone, elotuzumab did not demonstrate single-agent activity. The anti-CD38 monoclonal antibodies, including daratumumab and SAR650984, however, have been particularly impressive in early trials for myeloma patients, demonstrating their ability to effectively kill myeloma cells without the aid of steroids or other anti-myeloma agents.
Traduzione - Spagnolo Myeloma Today habla con el Dr. Thomas Martin
El Dr. Thomas Martin, miembro del Grupo Internacional de Trabajo del Mieloma (IMWG), es director asociado del programa de mieloma en el Centro Médico de la Universidad de California en San Francisco (UCSF). En la UCSF se ha tratado a más pacientes con el nuevo anticuerpo monoclonal anti-CD38 en los ensayos clínicos del Dr. Martin que en cualquier otro centro en el mundo.
¿Podría darnos un contexto para el uso de SAR650984 en el mieloma?
En los últimos 5-10 años, el tratamiento del mieloma múltiple ha girado en torno a dos tipos de fármacos, los inhibidores del proteasoma Velcade® (bortezomib) y Kyprolis® (carfilzomib) y los fármacos inmunomoduladores (también denominados IMiD®), como Thalomid® (talidomida), Revlimid® (lenalidomida) y Pomalyst® (pomalidomida). Yo creo que estos fármacos son muy eficaces porque sabemos que tienen en efecto importante como agentes únicos en el ámbito del mieloma, generando buenas respuestas cuando se usan solos, sin ningún otro tratamiento antimieloma. En mi opinión, los anticuerpos monoclonales, incluido SAR650984 (un anticuerpo monoclonal anti-CD38) también tienen el potencial de ser fármacos muy eficaces porque, en ensayos en fase temprana, hemos observado respuestas importantes (sobre todo con anticuerpos anti-CD38 como SAR650984) en pacientes con mieloma que habían recibido muchos tratamientos previos y cuyo mieloma no ha respondido a otros tratamientos.
Los anticuerpos monoclonales son un nuevo tipo de fármacos inmunoterapéuticos que han sido ampliamente probados y selectivamente aprobados para otros cánceres. Elotuzumab, un anticuerpo monoclonal anti-CS1, fue el primero que se probó con éxito en el mieloma, y ahora está presente en los ensayos de fase III combinado con Revlimid más dexametasona tanto para el mieloma recién diagnosticado como para el mieloma recaído/resistente. A pesar de haber sido muy eficaz combinado con Revlimid/dexametasona, elotuzumab no mostró ningún efecto como agente único. Sin embargo, los anticuerpos monoclonales anti-CD38, incluidos daratumumab y SAR650984, han tenido resultados particularmente impresionantes en los ensayos tempranos para los pacientes con mieloma, demostrando su capacidad para matar eficazmente las células del mieloma sin la ayuda de esteroides ni otros agentes antimieloma.
More
Less
Titoli di studio per la traduzione
Master's degree - Pompeu Fabra University, Barcelona
Esperienza
Anni di esperienza: 19 Registrato in ProZ.com: Feb 2006. Membro ProZ.com da: Jun 2011.
Credenziali
Da Inglese a Spagnolo (Universitat Pompeu Fabra, verified) Da Tedesco a Spagnolo (Universitat Pompeu Fabra, verified)
I got my start translating in an agency dedicated to sworn translations and interpreting, where I also worked as an interpreter from English, German, and Italian into Spanish and vice versa at the courts, the public prosecutor's offices, and the police stations in Barcelona.
Later I worked in a company translating and proofreading medical and pharmaceutical texts from English and German into Spanish. During this period I also translated various equestrian books from German into Spanish for a publishing house.
In parallel to that I have worked for SEM (Medical Emergency System) and for other companies nationally and internationally as a medical and social telephone interpreter from English, German, French, and Italian into Spanish, and vice versa. I have combined this work with video and on-site interpretations.
Lately I have translated several scientific articles from English into Spanish for the International Myeloma Foundation, PETHEMA, and Hospital Clínic, where I have worked as a Patient Manager and gained deep insight into the nature, diagnosis, prognostic factors, evolution, and treatment of multiple myeloma and other hematologic diseases.
Membro dal Jun '11
